Biopharma News, In Brief
J&J halts development of once-monthly Risperdal Consta: Johnson & Johnson announced it is pulling the plug on development of the once-monthly version of the atypical antipsychotic Risperdal Consta, the long-acting version of risperidone currently approved for twice-monthly use, partner Alkermes announced Aug. 26. The decision will allow J&J to focus its efforts on directing once-monthly antipsychotic scripts to its newly approved once-monthly Invega Sustenna (paliperidone palmitate) (1"The Pink Sheet" DAILY, Aug. 3, 2009). Invega has not done well commercially, and J&J is hoping the long-acting version will improve its share based on the compliance advantage (2"The Pink Sheet," July 27, 2009). Another factor that may have played into J&J streamlining its efforts: future competition from Lilly, which also is pursuing a long-acting injectable version of its best-selling antipsychotic Zyprexa (olanzapine). Lazard analyst Terrence Flynn is maintaining estimates of Consta sales, pending data in 2H09 from J&J's second head-to-head comparison of Invega Sustenna and Risperdal Consta, which uses a higher initiation dose of Sustenna (150 vs. 50 mg); Sustenna failed to show non-inferiority in the first head-to-head against Consta
You may also be interested in...
Genmab and partner GlaxoSmithKline reported August 17 disappointing top-line results from a Phase II study of their anti-CD 20 antibody Arzerra in rituximab-refractory follicular non-Hodgkin's lymphoma, calling into question the biotech's future as an independent entity
First public offering for the pharmaceutical sector in 21 months suggests a financial thaw, but unlikely to spark an additional flood of deals.
Wall St. analysts offer differing perspectives on the drug's commercial outlook.